Japan Drug Pricing
Analysis of Japan NHI pricing for global pharma market access teams.
Japan's formal cost-effectiveness evaluation (CEA) system layers ICER-based price adjustments on top of the existing NHI pricing framework — with scope expanding under FY2026 reforms. Here's what pharma market access teams need to plan for before NHI listing.
Read more →Japan's NHI covers diabetes drugs across DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 agonists — but tight restrictions, Market Expansion Repricing risk, and annual price revisions shape the real revenue picture. Here's what pharma market access teams need to understand.
Read more →Japan's NHI oncology pricing combines comparator-based methodology, foreign reference pricing, Market Expansion Repricing risk, and evolving cost-effectiveness rules. This guide explains what pharma market access teams need to know to model Japan cancer drug revenue accurately.
Read more →Japan's SAKIGAKE designation offers pharmaceutical companies a 10–20% NHI pricing premium and expedited review for innovative therapies. Learn how this system—and the newer Rapid Introduction Premium—shapes launch sequencing and pricing strategy for global market access teams.
Read more →Japan's April 2026 NHI drug price revision cut prices 4.02% on a spending basis. Here's what changed structurally and which drugs were hit hardest.
Read more →Japan revises NHI drug prices every April. Here is how the MHLW revision cycle works, what drives price cuts, and what global market access teams need to track.
Read more →